Janux Therapeutics (JANX) Revenue (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Revenue data on file, last reported at $3.7 million in Q1 2026.

• On a quarterly basis, Revenue changed N/A year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $13.7 million, a 47.1% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, down 5.55% from the prior year.
• Revenue for Q1 2026 stood at $3.7 million, down from $10.0 million in the prior quarter.
• Over the last five years, Revenue for JANX reached as high as $10.0 million in Q3 2025 and fell as low as $439000.0 in Q3 2024.
• Historically, Revenue has averaged $3.2 million across 5 years, with a median of $2.4 million in 2022.
• Across the five-year window, Revenue plunged 82.56% in 2024 and surged 2177.9% in 2025, its largest moves.
• Year by year, Revenue stood at $2.8 million in 2022, then declined by 13.5% to $2.5 million in 2023, then plunged by 82.16% to $439000.0 in 2024, then jumped by 2177.9% to $10.0 million in 2025, then slumped by 62.67% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $3.7 million in Q1 2026, $10.0 million in Q3 2025, and $439000.0 in Q3 2024.